EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
111.12
+1.34 (+1.22%)
As of 2:36PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close109.78
Open111.32
Bid111.14 x 1000
Ask111.23 x 1100
Day's Range109.46 - 112.15
52 Week Range47.78 - 114.36
Volume396,433
Avg. Volume1,772,000
Market Cap14.35B
Beta (3Y Monthly)2.38
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est114.00
Trade prices are not sourced from all markets
  • Markit2 days ago

    See what the IHS Markit Score report has to say about Exact Sciences Corp.

    Exact Sciences Corp NASDAQ:EXASView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for EXAS with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold EXAS had net inflows of $1.92 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Benzinga13 days ago

    Jim Cramer Gives His Opinion On Wendy's, Exelon And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said Wendys Co (NASDAQ: WEN ) is one of his absolute favorites. Cramer is a buyer of Zoetis Inc (NYSE: ZTS ). He added that the stock hit another ...

  • Exact Sciences to participate in June investor conferences
    PR Newswire17 days ago

    Exact Sciences to participate in June investor conferences

    MADISON, Wis., May 31, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer
    Zacks20 days ago

    The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

    The Zacks Analyst Blog Highlights: Guardant, Illumina, Exact Sciences and Pfizer

  • 3 Stocks to Win Big in the Fight Against Cancer
    Zacks24 days ago

    3 Stocks to Win Big in the Fight Against Cancer

    We highlight three stocks that are using innovative ways to treat cancer, also called malignancy. These stocks are also great long-term investments.

  • Exact Sciences Corporation (NASDAQ:EXAS): When Will It Breakeven?
    Simply Wall St.25 days ago

    Exact Sciences Corporation (NASDAQ:EXAS): When Will It Breakeven?

    Exact Sciences Corporation's (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on...

  • Exact Sciences Advances Pipeline Capabilities with Mayo Clinic
    PR Newswire28 days ago

    Exact Sciences Advances Pipeline Capabilities with Mayo Clinic

    SAN DIEGO, May 20, 2019 /PRNewswire/ -- Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive Disease Week (DDW) 2019, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. "These pancreatic cancer data showcase the strength of our marker discovery collaboration with Mayo Clinic, a partnership that is fueling our product pipeline," said Kevin Conroy, chairman and CEO of Exact Sciences.

  • Exact Sciences Presents New Data Reinforcing Performance of Cologuard®
    PR Newswirelast month

    Exact Sciences Presents New Data Reinforcing Performance of Cologuard®

    SAN DIEGO, May 17, 2019 /PRNewswire/ -- New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location. The findings, presented at Digestive Disease Week (DDW) 2019, reinforce the role of Cologuard in improving colorectal cancer screening rates and patient outcomes. Despite recent efforts to positively impact colorectal cancer screening rates in the US, one-in-three Americans ages 50 to 75 are not up to date with recommended screening.i New research suggests the Cologuard test can help screen more people.

  • Exact Sciences returning $61K in WEDC tax credits because jobs were created outside Wisconsin: AP
    American City Business Journalslast month

    Exact Sciences returning $61K in WEDC tax credits because jobs were created outside Wisconsin: AP

    Exact Sciences Corp., the Madison-based maker of the Cologuard take-home colon cancer test and one of the largest public companies in Wisconsin, is reportedly returning $61,000 it received from the Wisconsin Economic Development Corp. because a certain number of jobs the money was intended for were created outside of Wisconsin. In 2015, Exact Sciences was approved by the WEDC to receive up to $9 million in tax credits if it added at least 750 jobs and made a capital investment of $26 million by 2020. Under the agreement, Exact Sciences would receive the WEDC tax incentives by investing in capital expenditures in Wisconsin and creating 758 new full-time positions – with an average wage of $24.47 per hour – in the state by Dec. 31, 2020.

  • 3 Top Healthcare Stocks to Buy in May
    Motley Foollast month

    3 Top Healthcare Stocks to Buy in May

    These look like great picks to buy in May before you go away.

  • Guardant Health Takes Aim at Exact Sciences
    Motley Foollast month

    Guardant Health Takes Aim at Exact Sciences

    A new study is planned that could someday reshape colon cancer screenings.

  • Why Exact Sciences Shrugged Off the Moody Market in April
    Motley Foollast month

    Why Exact Sciences Shrugged Off the Moody Market in April

    Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.

  • The stock market’s reaction to this one word from the Fed’s Powell shows investors should be careful
    MarketWatch2 months ago

    The stock market’s reaction to this one word from the Fed’s Powell shows investors should be careful

    Sometimes the U.S. stock market sends a clear, unambiguous message. The message the stock market sent during Federal Reserve Chairman Jerome Powell’s press conference Wednesday says that the market is vulnerable. • The chart shows that the stock market rose immediately after the Fed decision was announced.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of EXAS earnings conference call or presentation 30-Apr-19 9:00pm GMT

    Q1 2019 Exact Sciences Corp Earnings Call

  • Exact Sciences Corp (EXAS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Exact Sciences Corp (EXAS) Q1 2019 Earnings Call Transcript

    EXAS earnings call for the period ending March 31, 2019.

  • Exact Sciences to participate in May investor conferences
    PR Newswire2 months ago

    Exact Sciences to participate in May investor conferences

    MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.

  • What You'll Want to Know About Exact Sciences' Q1 Earnings
    Motley Fool2 months ago

    What You'll Want to Know About Exact Sciences' Q1 Earnings

    The maker of the Cologuard colorectal cancer screening test reported tremendous revenue growth -- but a worsening bottom line.

  • Associated Press2 months ago

    Exact Sciences: 1Q Earnings Snapshot

    The Madison, Wisconsin-based company said it had a loss of 66 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...

  • Exact Sciences reports 79% jump in Cologuard test volume, first-quarter revenue
    American City Business Journals2 months ago

    Exact Sciences reports 79% jump in Cologuard test volume, first-quarter revenue

    The company raised its guidance for its fiscal 2019, anticipating revenues between $725 million and $740 million.

  • First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively
    PR Newswire2 months ago

    First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively

    - Estimated Cologuard market share increased to 4.6 percent during the first quarter - Nearly 14,000 health care providers ordered their initial Cologuard test during the first quarter, and more than 160,000 ...

  • ACCESSWIRE2 months ago

    EXACT Sciences Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 30, 2019 / EXACT Sciences Corp. (NASDAQ: EXAS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 5:00 PM ...

  • The 5 Hottest Earnings Charts This Week
    Zacks2 months ago

    The 5 Hottest Earnings Charts This Week

    These 5 stocks have had big rallies in 2019. Are they too hot to handle?